Orally administered proteases in aesthetic surgery.
Identifieur interne : 004D20 ( PubMed/Curation ); précédent : 004D19; suivant : 004D21Orally administered proteases in aesthetic surgery.
Auteurs : M. Dusková [République tchèque] ; M. WaldSource :
- Aesthetic plastic surgery [ 0364-216X ]
Descripteurs français
- KwdFr :
- Administration par voie orale, Adulte, Adulte d'âge moyen, Aescine (administration et posologie), Association médicamenteuse, Blépharoplastie, Complications postopératoires (), Humains, Hydrolases (administration et posologie), Hémostatiques (administration et posologie), Rutoside (administration et posologie), Soins postopératoires, Sujet âgé, Étamsylate (administration et posologie), Études prospectives.
- MESH :
- administration et posologie : Aescine, Hydrolases, Hémostatiques, Rutoside, Étamsylate.
- Administration par voie orale, Adulte, Adulte d'âge moyen, Association médicamenteuse, Blépharoplastie, Complications postopératoires, Humains, Soins postopératoires, Sujet âgé, Études prospectives.
English descriptors
- KwdEn :
- Administration, Oral, Adult, Aged, Blepharoplasty, Drug Combinations, Escin (administration & dosage), Ethamsylate (administration & dosage), Hemostatics (administration & dosage), Humans, Hydrolases (administration & dosage), Middle Aged, Postoperative Care, Postoperative Complications (prevention & control), Prospective Studies, Rutin (administration & dosage).
- MESH :
- chemical , administration & dosage : Escin, Ethamsylate, Hemostatics, Hydrolases, Rutin.
- chemical : Drug Combinations.
- prevention & control : Postoperative Complications.
- Administration, Oral, Adult, Aged, Blepharoplasty, Humans, Middle Aged, Postoperative Care, Prospective Studies.
Abstract
Increasing demand for shortening the sequel period after aesthetic surgery has led to comparative testing of optional approaches. Systemic enzyme therapy with its pharmacological effects represents a preventive and curative option for inflammatory process including healing. Excellent results were presented, namely, in the treatment of secondary lymphoedema. The incidence of hematoma, edema, and pain was followed, and the results were compared in a randomized group of 20 patients with upper eyelid blepharoplasty treated with proteases (Wobenzym drg) and in a similar group treated with systemic antiedema and hemostyptic therapy (Dicynone drg and Reparil drg). No undesirable side effects were observed. In addition, proteases apparently have no limitation for patients with the risk of concurrent cardiovascular, hepatic, or renal diseases.
PubMed: 10022937
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: Pour aller vers cette notice dans l'étape Curation :004D20
Links to Exploration step
pubmed:10022937Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Orally administered proteases in aesthetic surgery.</title>
<author><name sortKey="Duskova, M" sort="Duskova, M" uniqKey="Duskova M" first="M" last="Dusková">M. Dusková</name>
<affiliation wicri:level="1"><nlm:affiliation>Klinika plastické chirurgie, Prague, Czech Republic.</nlm:affiliation>
<country xml:lang="fr">République tchèque</country>
<wicri:regionArea>Klinika plastické chirurgie, Prague</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Wald, M" sort="Wald, M" uniqKey="Wald M" first="M" last="Wald">M. Wald</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="????"><PubDate><MedlineDate>1999 Jan-Feb</MedlineDate>
</PubDate>
</date>
<idno type="RBID">pubmed:10022937</idno>
<idno type="pmid">10022937</idno>
<idno type="wicri:Area/PubMed/Corpus">004D20</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">004D20</idno>
<idno type="wicri:Area/PubMed/Curation">004D20</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">004D20</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">Orally administered proteases in aesthetic surgery.</title>
<author><name sortKey="Duskova, M" sort="Duskova, M" uniqKey="Duskova M" first="M" last="Dusková">M. Dusková</name>
<affiliation wicri:level="1"><nlm:affiliation>Klinika plastické chirurgie, Prague, Czech Republic.</nlm:affiliation>
<country xml:lang="fr">République tchèque</country>
<wicri:regionArea>Klinika plastické chirurgie, Prague</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Wald, M" sort="Wald, M" uniqKey="Wald M" first="M" last="Wald">M. Wald</name>
</author>
</analytic>
<series><title level="j">Aesthetic plastic surgery</title>
<idno type="ISSN">0364-216X</idno>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Administration, Oral</term>
<term>Adult</term>
<term>Aged</term>
<term>Blepharoplasty</term>
<term>Drug Combinations</term>
<term>Escin (administration & dosage)</term>
<term>Ethamsylate (administration & dosage)</term>
<term>Hemostatics (administration & dosage)</term>
<term>Humans</term>
<term>Hydrolases (administration & dosage)</term>
<term>Middle Aged</term>
<term>Postoperative Care</term>
<term>Postoperative Complications (prevention & control)</term>
<term>Prospective Studies</term>
<term>Rutin (administration & dosage)</term>
</keywords>
<keywords scheme="KwdFr" xml:lang="fr"><term>Administration par voie orale</term>
<term>Adulte</term>
<term>Adulte d'âge moyen</term>
<term>Aescine (administration et posologie)</term>
<term>Association médicamenteuse</term>
<term>Blépharoplastie</term>
<term>Complications postopératoires ()</term>
<term>Humains</term>
<term>Hydrolases (administration et posologie)</term>
<term>Hémostatiques (administration et posologie)</term>
<term>Rutoside (administration et posologie)</term>
<term>Soins postopératoires</term>
<term>Sujet âgé</term>
<term>Étamsylate (administration et posologie)</term>
<term>Études prospectives</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Escin</term>
<term>Ethamsylate</term>
<term>Hemostatics</term>
<term>Hydrolases</term>
<term>Rutin</term>
</keywords>
<keywords scheme="MESH" type="chemical" xml:lang="en"><term>Drug Combinations</term>
</keywords>
<keywords scheme="MESH" qualifier="administration et posologie" xml:lang="fr"><term>Aescine</term>
<term>Hydrolases</term>
<term>Hémostatiques</term>
<term>Rutoside</term>
<term>Étamsylate</term>
</keywords>
<keywords scheme="MESH" qualifier="prevention & control" xml:lang="en"><term>Postoperative Complications</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Administration, Oral</term>
<term>Adult</term>
<term>Aged</term>
<term>Blepharoplasty</term>
<term>Humans</term>
<term>Middle Aged</term>
<term>Postoperative Care</term>
<term>Prospective Studies</term>
</keywords>
<keywords scheme="MESH" xml:lang="fr"><term>Administration par voie orale</term>
<term>Adulte</term>
<term>Adulte d'âge moyen</term>
<term>Association médicamenteuse</term>
<term>Blépharoplastie</term>
<term>Complications postopératoires</term>
<term>Humains</term>
<term>Soins postopératoires</term>
<term>Sujet âgé</term>
<term>Études prospectives</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Increasing demand for shortening the sequel period after aesthetic surgery has led to comparative testing of optional approaches. Systemic enzyme therapy with its pharmacological effects represents a preventive and curative option for inflammatory process including healing. Excellent results were presented, namely, in the treatment of secondary lymphoedema. The incidence of hematoma, edema, and pain was followed, and the results were compared in a randomized group of 20 patients with upper eyelid blepharoplasty treated with proteases (Wobenzym drg) and in a similar group treated with systemic antiedema and hemostyptic therapy (Dicynone drg and Reparil drg). No undesirable side effects were observed. In addition, proteases apparently have no limitation for patients with the risk of concurrent cardiovascular, hepatic, or renal diseases.</div>
</front>
</TEI>
<pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">10022937</PMID>
<DateCreated><Year>1999</Year>
<Month>03</Month>
<Day>24</Day>
</DateCreated>
<DateCompleted><Year>1999</Year>
<Month>03</Month>
<Day>24</Day>
</DateCompleted>
<DateRevised><Year>2013</Year>
<Month>11</Month>
<Day>21</Day>
</DateRevised>
<Article PubModel="Print"><Journal><ISSN IssnType="Print">0364-216X</ISSN>
<JournalIssue CitedMedium="Print"><Volume>23</Volume>
<Issue>1</Issue>
<PubDate><MedlineDate>1999 Jan-Feb</MedlineDate>
</PubDate>
</JournalIssue>
<Title>Aesthetic plastic surgery</Title>
<ISOAbbreviation>Aesthetic Plast Surg</ISOAbbreviation>
</Journal>
<ArticleTitle>Orally administered proteases in aesthetic surgery.</ArticleTitle>
<Pagination><MedlinePgn>41-4</MedlinePgn>
</Pagination>
<Abstract><AbstractText>Increasing demand for shortening the sequel period after aesthetic surgery has led to comparative testing of optional approaches. Systemic enzyme therapy with its pharmacological effects represents a preventive and curative option for inflammatory process including healing. Excellent results were presented, namely, in the treatment of secondary lymphoedema. The incidence of hematoma, edema, and pain was followed, and the results were compared in a randomized group of 20 patients with upper eyelid blepharoplasty treated with proteases (Wobenzym drg) and in a similar group treated with systemic antiedema and hemostyptic therapy (Dicynone drg and Reparil drg). No undesirable side effects were observed. In addition, proteases apparently have no limitation for patients with the risk of concurrent cardiovascular, hepatic, or renal diseases.</AbstractText>
</Abstract>
<AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Dusková</LastName>
<ForeName>M</ForeName>
<Initials>M</Initials>
<AffiliationInfo><Affiliation>Klinika plastické chirurgie, Prague, Czech Republic.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Wald</LastName>
<ForeName>M</ForeName>
<Initials>M</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList><PublicationType UI="D016430">Clinical Trial</PublicationType>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D016449">Randomized Controlled Trial</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo><Country>United States</Country>
<MedlineTA>Aesthetic Plast Surg</MedlineTA>
<NlmUniqueID>7701756</NlmUniqueID>
<ISSNLinking>0364-216X</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList><Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D004338">Drug Combinations</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D006490">Hemostatics</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>24YL531VOH</RegistryNumber>
<NameOfSubstance UI="D004979">Ethamsylate</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>5G06TVY3R7</RegistryNumber>
<NameOfSubstance UI="D012431">Rutin</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>6805-41-0</RegistryNumber>
<NameOfSubstance UI="D004928">Escin</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>72506-65-1</RegistryNumber>
<NameOfSubstance UI="C023295">Wobenzym</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>EC 3.-</RegistryNumber>
<NameOfSubstance UI="D006867">Hydrolases</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList><MeshHeading><DescriptorName UI="D000284" MajorTopicYN="N">Administration, Oral</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D019882" MajorTopicYN="Y">Blepharoplasty</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D004338" MajorTopicYN="N">Drug Combinations</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D004928" MajorTopicYN="N">Escin</DescriptorName>
<QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D004979" MajorTopicYN="N">Ethamsylate</DescriptorName>
<QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D006490" MajorTopicYN="N">Hemostatics</DescriptorName>
<QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D006867" MajorTopicYN="N">Hydrolases</DescriptorName>
<QualifierName UI="Q000008" MajorTopicYN="Y">administration & dosage</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D011182" MajorTopicYN="N">Postoperative Care</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D011183" MajorTopicYN="N">Postoperative Complications</DescriptorName>
<QualifierName UI="Q000517" MajorTopicYN="Y">prevention & control</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D011446" MajorTopicYN="N">Prospective Studies</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D012431" MajorTopicYN="N">Rutin</DescriptorName>
<QualifierName UI="Q000008" MajorTopicYN="Y">administration & dosage</QualifierName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>
<PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1999</Year>
<Month>2</Month>
<Day>18</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline"><Year>1999</Year>
<Month>2</Month>
<Day>18</Day>
<Hour>0</Hour>
<Minute>1</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="entrez"><Year>1999</Year>
<Month>2</Month>
<Day>18</Day>
<Hour>0</Hour>
<Minute>0</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList><ArticleId IdType="pubmed">10022937</ArticleId>
</ArticleIdList>
</PubmedData>
</pubmed>
</record>
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/LymphedemaV1/Data/PubMed/Curation
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 004D20 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Curation/biblio.hfd -nk 004D20 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien |wiki= Wicri/Sante |area= LymphedemaV1 |flux= PubMed |étape= Curation |type= RBID |clé= pubmed:10022937 |texte= Orally administered proteases in aesthetic surgery. }}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Curation/RBID.i -Sk "pubmed:10022937" \ | HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Curation/biblio.hfd \ | NlmPubMed2Wicri -a LymphedemaV1
This area was generated with Dilib version V0.6.31. |